Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Identifieur interne : 000609 ( PubMed/Checkpoint ); précédent : 000608; suivant : 000610Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Auteurs : Ghassan K. Abou-Alfa ; Jean-Frederic Blanc [France] ; Steven Miles [États-Unis] ; Tom Ganten [Allemagne] ; Jörg Trojan [Allemagne] ; Jonathan Cebon [Australie] ; Andre K. Liem [États-Unis] ; Lara Lipton [Australie] ; Charu Gupta [États-Unis] ; Benjamin Wu [États-Unis] ; Michael Bass [États-Unis] ; Ellen Hollywood [États-Unis] ; Jennifer Ma [États-Unis] ; Margaret Bradley [États-Unis] ; Jason Litten [États-Unis] ; Leonard B. Saltz [États-Unis]Source :
- The oncologist [ 1549-490X ] ; 2017.
Abstract
Trebananib leveraging anti-angiogenic mechanism that is distinct from the classic sorafenib anti-vascular endothelial growth factor inhibition did not demonstrate improved progression-free survival at 4 months in patients with advanced hepatocellular carcinoma (HCC).In support of previously reported high Ang-2 levels' association with poor outcome in HCC for patients, trebananib treatment with lower baseline Ang-2 at study entry was associated with improved overall survival to 22 months and may suggest future studies to be performed within the context of low baseline Ang-2.
DOI: 10.1634/theoncologist.2017-0058
PubMed: 28592620
Affiliations:
- Allemagne, Australie, France, États-Unis
- Aquitaine, Bade-Wurtemberg, Californie, District de Darmstadt, District de Karlsruhe, Hesse (Land), Nouvelle-Aquitaine, État de New York
- Bordeaux, Francfort-sur-le-Main, Heidelberg
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:28592620Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.</title><author><name sortKey="Abou Alfa, Ghassan K" sort="Abou Alfa, Ghassan K" uniqKey="Abou Alfa G" first="Ghassan K" last="Abou-Alfa">Ghassan K. Abou-Alfa</name><affiliation><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, New York, USA abou-alg@mskcc.org.</nlm:affiliation><wicri:noCountry code="subField">USA abou-alg@mskcc.org.</wicri:noCountry></affiliation></author><author><name sortKey="Blanc, Jean Frederic" sort="Blanc, Jean Frederic" uniqKey="Blanc J" first="Jean-Frederic" last="Blanc">Jean-Frederic Blanc</name><affiliation wicri:level="3"><nlm:affiliation>Hôpital Saint-André, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Saint-André, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Miles, Steven" sort="Miles, Steven" uniqKey="Miles S" first="Steven" last="Miles">Steven Miles</name><affiliation wicri:level="2"><nlm:affiliation>Cedars Sinai Hospital, Los Angeles, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cedars Sinai Hospital, Los Angeles, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Ganten, Tom" sort="Ganten, Tom" uniqKey="Ganten T" first="Tom" last="Ganten">Tom Ganten</name><affiliation wicri:level="3"><nlm:affiliation>University of Heidelberg, Heidelberg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>University of Heidelberg, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Trojan, Jorg" sort="Trojan, Jorg" uniqKey="Trojan J" first="Jörg" last="Trojan">Jörg Trojan</name><affiliation wicri:level="3"><nlm:affiliation>Johann Wolfgang Goethe University, Frankfurt, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Johann Wolfgang Goethe University, Frankfurt</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Francfort-sur-le-Main</settlement></placeName></affiliation></author><author><name sortKey="Cebon, Jonathan" sort="Cebon, Jonathan" uniqKey="Cebon J" first="Jonathan" last="Cebon">Jonathan Cebon</name><affiliation wicri:level="1"><nlm:affiliation>Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Liem, Andre K" sort="Liem, Andre K" uniqKey="Liem A" first="Andre K" last="Liem">Andre K. Liem</name><affiliation wicri:level="2"><nlm:affiliation>Translational Oncology Research International, Long Beach, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Translational Oncology Research International, Long Beach, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Lipton, Lara" sort="Lipton, Lara" uniqKey="Lipton L" first="Lara" last="Lipton">Lara Lipton</name><affiliation wicri:level="1"><nlm:affiliation>Western Hospital, Footscray, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Western Hospital, Footscray, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Gupta, Charu" sort="Gupta, Charu" uniqKey="Gupta C" first="Charu" last="Gupta">Charu Gupta</name><affiliation wicri:level="2"><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Amgen Inc., Thousand Oaks, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Wu, Benjamin" sort="Wu, Benjamin" uniqKey="Wu B" first="Benjamin" last="Wu">Benjamin Wu</name><affiliation wicri:level="2"><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Amgen Inc., Thousand Oaks, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Bass, Michael" sort="Bass, Michael" uniqKey="Bass M" first="Michael" last="Bass">Michael Bass</name><affiliation wicri:level="2"><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Amgen Inc., Thousand Oaks, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Hollywood, Ellen" sort="Hollywood, Ellen" uniqKey="Hollywood E" first="Ellen" last="Hollywood">Ellen Hollywood</name><affiliation wicri:level="2"><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Sloan Kettering Cancer Center, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Ma, Jennifer" sort="Ma, Jennifer" uniqKey="Ma J" first="Jennifer" last="Ma">Jennifer Ma</name><affiliation wicri:level="2"><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Sloan Kettering Cancer Center, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Bradley, Margaret" sort="Bradley, Margaret" uniqKey="Bradley M" first="Margaret" last="Bradley">Margaret Bradley</name><affiliation wicri:level="2"><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Sloan Kettering Cancer Center, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Litten, Jason" sort="Litten, Jason" uniqKey="Litten J" first="Jason" last="Litten">Jason Litten</name><affiliation wicri:level="2"><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Amgen Inc., Thousand Oaks, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Saltz, Leonard B" sort="Saltz, Leonard B" uniqKey="Saltz L" first="Leonard B" last="Saltz">Leonard B. Saltz</name><affiliation wicri:level="2"><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Sloan Kettering Cancer Center, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28592620</idno><idno type="pmid">28592620</idno><idno type="doi">10.1634/theoncologist.2017-0058</idno><idno type="wicri:Area/PubMed/Corpus">000896</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000896</idno><idno type="wicri:Area/PubMed/Curation">000893</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000893</idno><idno type="wicri:Area/PubMed/Checkpoint">000893</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000893</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.</title><author><name sortKey="Abou Alfa, Ghassan K" sort="Abou Alfa, Ghassan K" uniqKey="Abou Alfa G" first="Ghassan K" last="Abou-Alfa">Ghassan K. Abou-Alfa</name><affiliation><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, New York, USA abou-alg@mskcc.org.</nlm:affiliation><wicri:noCountry code="subField">USA abou-alg@mskcc.org.</wicri:noCountry></affiliation></author><author><name sortKey="Blanc, Jean Frederic" sort="Blanc, Jean Frederic" uniqKey="Blanc J" first="Jean-Frederic" last="Blanc">Jean-Frederic Blanc</name><affiliation wicri:level="3"><nlm:affiliation>Hôpital Saint-André, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Saint-André, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Miles, Steven" sort="Miles, Steven" uniqKey="Miles S" first="Steven" last="Miles">Steven Miles</name><affiliation wicri:level="2"><nlm:affiliation>Cedars Sinai Hospital, Los Angeles, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cedars Sinai Hospital, Los Angeles, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Ganten, Tom" sort="Ganten, Tom" uniqKey="Ganten T" first="Tom" last="Ganten">Tom Ganten</name><affiliation wicri:level="3"><nlm:affiliation>University of Heidelberg, Heidelberg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>University of Heidelberg, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Trojan, Jorg" sort="Trojan, Jorg" uniqKey="Trojan J" first="Jörg" last="Trojan">Jörg Trojan</name><affiliation wicri:level="3"><nlm:affiliation>Johann Wolfgang Goethe University, Frankfurt, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Johann Wolfgang Goethe University, Frankfurt</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Francfort-sur-le-Main</settlement></placeName></affiliation></author><author><name sortKey="Cebon, Jonathan" sort="Cebon, Jonathan" uniqKey="Cebon J" first="Jonathan" last="Cebon">Jonathan Cebon</name><affiliation wicri:level="1"><nlm:affiliation>Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Liem, Andre K" sort="Liem, Andre K" uniqKey="Liem A" first="Andre K" last="Liem">Andre K. Liem</name><affiliation wicri:level="2"><nlm:affiliation>Translational Oncology Research International, Long Beach, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Translational Oncology Research International, Long Beach, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Lipton, Lara" sort="Lipton, Lara" uniqKey="Lipton L" first="Lara" last="Lipton">Lara Lipton</name><affiliation wicri:level="1"><nlm:affiliation>Western Hospital, Footscray, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Western Hospital, Footscray, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Gupta, Charu" sort="Gupta, Charu" uniqKey="Gupta C" first="Charu" last="Gupta">Charu Gupta</name><affiliation wicri:level="2"><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Amgen Inc., Thousand Oaks, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Wu, Benjamin" sort="Wu, Benjamin" uniqKey="Wu B" first="Benjamin" last="Wu">Benjamin Wu</name><affiliation wicri:level="2"><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Amgen Inc., Thousand Oaks, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Bass, Michael" sort="Bass, Michael" uniqKey="Bass M" first="Michael" last="Bass">Michael Bass</name><affiliation wicri:level="2"><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Amgen Inc., Thousand Oaks, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Hollywood, Ellen" sort="Hollywood, Ellen" uniqKey="Hollywood E" first="Ellen" last="Hollywood">Ellen Hollywood</name><affiliation wicri:level="2"><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Sloan Kettering Cancer Center, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Ma, Jennifer" sort="Ma, Jennifer" uniqKey="Ma J" first="Jennifer" last="Ma">Jennifer Ma</name><affiliation wicri:level="2"><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Sloan Kettering Cancer Center, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Bradley, Margaret" sort="Bradley, Margaret" uniqKey="Bradley M" first="Margaret" last="Bradley">Margaret Bradley</name><affiliation wicri:level="2"><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Sloan Kettering Cancer Center, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Litten, Jason" sort="Litten, Jason" uniqKey="Litten J" first="Jason" last="Litten">Jason Litten</name><affiliation wicri:level="2"><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Amgen Inc., Thousand Oaks, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Saltz, Leonard B" sort="Saltz, Leonard B" uniqKey="Saltz L" first="Leonard B" last="Saltz">Leonard B. Saltz</name><affiliation wicri:level="2"><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Sloan Kettering Cancer Center, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><series><title level="j">The oncologist</title><idno type="eISSN">1549-490X</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Trebananib leveraging anti-angiogenic mechanism that is distinct from the classic sorafenib anti-vascular endothelial growth factor inhibition did not demonstrate improved progression-free survival at 4 months in patients with advanced hepatocellular carcinoma (HCC).In support of previously reported high Ang-2 levels' association with poor outcome in HCC for patients, trebananib treatment with lower baseline Ang-2 at study entry was associated with improved overall survival to 22 months and may suggest future studies to be performed within the context of low baseline Ang-2.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">28592620</PMID><DateCreated><Year>2017</Year><Month>06</Month><Day>08</Day></DateCreated><DateRevised><Year>2017</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1549-490X</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>7</Issue><PubDate><Year>2017</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The oncologist</Title><ISOAbbreviation>Oncologist</ISOAbbreviation></Journal><ArticleTitle>Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.</ArticleTitle><Pagination><MedlinePgn>780-e65</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1634/theoncologist.2017-0058</ELocationID><Abstract><AbstractText Label="LESSONS LEARNED" NlmCategory="CONCLUSIONS">Trebananib leveraging anti-angiogenic mechanism that is distinct from the classic sorafenib anti-vascular endothelial growth factor inhibition did not demonstrate improved progression-free survival at 4 months in patients with advanced hepatocellular carcinoma (HCC).In support of previously reported high Ang-2 levels' association with poor outcome in HCC for patients, trebananib treatment with lower baseline Ang-2 at study entry was associated with improved overall survival to 22 months and may suggest future studies to be performed within the context of low baseline Ang-2.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Ang-1 and Ang-2 are angiopoietins thought to promote neovascularization via activation of the Tie-2 angiopoietin receptor. Trebananib sequesters Ang-1 and Ang-2, preventing interaction with the Tie-2 receptor. Trebananib plus sorafenib combination has acceptable toxicity. Elevated Ang-2 levels are associated with poor prognosis in hepatocellular carcinoma (HCC).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with HCC, Eastern Cooperative Oncology Group ≤2, and Childs-Pugh A received IV trebananib at 10 mg/kg or 15 mg/kg weekly plus sorafenib 400 mg orally twice daily. The study was planned for ≥78% progression-free survival (PFS) rate at 4 months relative to 62% for sorafenib historical control (power = 80% α = 0.20). Secondary endpoints included safety, tolerability, overall survival (OS), and multiple biomarkers, including serum Ang-2.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty patients were enrolled sequentially in each of the two nonrandomized cohorts. Demographics were comparable between the two arms and the historical controls. PFS rates at 4 months were 57% and 54% on the 10 mg/kg and 15 mg/kg trebananib cohorts, respectively. Median OS was 17 and 11 months, respectively. Grade 3 and above events noted in ≥10% of patients included fatigue, hypertension, diarrhea, liver failure, palmar-plantar erythrodysesthesia syndrome, dyspnea, and hypophosphatemia. One death was due to hepatic failure. Serum Ang-2 dichotomized at the median was associated with improved OS in both cohorts.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">There was no improvement in PFS rate at 4 months in either cohort, when compared with sorafenib historical control.</AbstractText><CopyrightInformation>© AlphaMedPress; the data published online to support this summary is the property of the authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abou-Alfa</LastName><ForeName>Ghassan K</ForeName><Initials>GK</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, New York, USA abou-alg@mskcc.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell Medical College, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blanc</LastName><ForeName>Jean-Frederic</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Hôpital Saint-André, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miles</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cedars Sinai Hospital, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganten</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojan</LastName><ForeName>Jörg</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Johann Wolfgang Goethe University, Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cebon</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liem</LastName><ForeName>Andre K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Translational Oncology Research International, Long Beach, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipton</LastName><ForeName>Lara</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Western Hospital, Footscray, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Charu</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Amgen Inc., Thousand Oaks, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Amgen Inc., Thousand Oaks, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bass</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Amgen Inc., Thousand Oaks, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hollywood</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradley</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Litten</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Amgen Inc., Thousand Oaks, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saltz</LastName><ForeName>Leonard B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell Medical College, New York, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Oncologist</MedlineTA><NlmUniqueID>9607837</NlmUniqueID><ISSNLinking>1083-7159</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2012 Dec 15;118(24):6152-61</RefSource><PMID Version="1">22692704</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2013 Jun;14(7):e283-8</RefSource><PMID Version="1">23725711</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2008 Jul 24;359(4):378-90</RefSource><PMID Version="1">18650514</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2014 Oct 15;120(20):3122-30</RefSource><PMID Version="1">24898783</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2010 Jun 1;16(11):3044-56</RefSource><PMID Version="1">20501621</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2016 Feb 1;122(3):367-77</RefSource><PMID Version="1">26540029</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Mol Ther. 2010 Aug;12(4):487-95</RefSource><PMID Version="1">20677100</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2004 May;40(5):799-807</RefSource><PMID Version="1">15094228</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Oncol Rep. 2009 Mar;11(2):111-6</RefSource><PMID Version="1">19216842</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2012 Apr 15;18(8):2290-300</RefSource><PMID Version="1">22374331</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>01</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>04</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28592620</ArticleId><ArticleId IdType="pii">theoncologist.2017-0058</ArticleId><ArticleId IdType="doi">10.1634/theoncologist.2017-0058</ArticleId><ArticleId IdType="pmc">PMC5507650</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>France</li><li>États-Unis</li></country><region><li>Aquitaine</li><li>Bade-Wurtemberg</li><li>Californie</li><li>District de Darmstadt</li><li>District de Karlsruhe</li><li>Hesse (Land)</li><li>Nouvelle-Aquitaine</li><li>État de New York</li></region><settlement><li>Bordeaux</li><li>Francfort-sur-le-Main</li><li>Heidelberg</li></settlement></list><tree><noCountry><name sortKey="Abou Alfa, Ghassan K" sort="Abou Alfa, Ghassan K" uniqKey="Abou Alfa G" first="Ghassan K" last="Abou-Alfa">Ghassan K. Abou-Alfa</name></noCountry><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Blanc, Jean Frederic" sort="Blanc, Jean Frederic" uniqKey="Blanc J" first="Jean-Frederic" last="Blanc">Jean-Frederic Blanc</name></region></country><country name="États-Unis"><region name="Californie"><name sortKey="Miles, Steven" sort="Miles, Steven" uniqKey="Miles S" first="Steven" last="Miles">Steven Miles</name></region><name sortKey="Bass, Michael" sort="Bass, Michael" uniqKey="Bass M" first="Michael" last="Bass">Michael Bass</name><name sortKey="Bradley, Margaret" sort="Bradley, Margaret" uniqKey="Bradley M" first="Margaret" last="Bradley">Margaret Bradley</name><name sortKey="Gupta, Charu" sort="Gupta, Charu" uniqKey="Gupta C" first="Charu" last="Gupta">Charu Gupta</name><name sortKey="Hollywood, Ellen" sort="Hollywood, Ellen" uniqKey="Hollywood E" first="Ellen" last="Hollywood">Ellen Hollywood</name><name sortKey="Liem, Andre K" sort="Liem, Andre K" uniqKey="Liem A" first="Andre K" last="Liem">Andre K. Liem</name><name sortKey="Litten, Jason" sort="Litten, Jason" uniqKey="Litten J" first="Jason" last="Litten">Jason Litten</name><name sortKey="Ma, Jennifer" sort="Ma, Jennifer" uniqKey="Ma J" first="Jennifer" last="Ma">Jennifer Ma</name><name sortKey="Saltz, Leonard B" sort="Saltz, Leonard B" uniqKey="Saltz L" first="Leonard B" last="Saltz">Leonard B. Saltz</name><name sortKey="Wu, Benjamin" sort="Wu, Benjamin" uniqKey="Wu B" first="Benjamin" last="Wu">Benjamin Wu</name></country><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Ganten, Tom" sort="Ganten, Tom" uniqKey="Ganten T" first="Tom" last="Ganten">Tom Ganten</name></region><name sortKey="Trojan, Jorg" sort="Trojan, Jorg" uniqKey="Trojan J" first="Jörg" last="Trojan">Jörg Trojan</name></country><country name="Australie"><noRegion><name sortKey="Cebon, Jonathan" sort="Cebon, Jonathan" uniqKey="Cebon J" first="Jonathan" last="Cebon">Jonathan Cebon</name></noRegion><name sortKey="Lipton, Lara" sort="Lipton, Lara" uniqKey="Lipton L" first="Lara" last="Lipton">Lara Lipton</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000609 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000609 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:28592620
|texte= Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:28592620" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |